Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva To Investigate High-Dose Copaxone

This article was originally published in The Pink Sheet Daily

Executive Summary

A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.

You may also be interested in...



Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

Compound fails to meet primary and secondary trial endpoints.

Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

Compound fails to meet primary and secondary trial endpoints.

Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says

Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)

Related Content

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel